This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, April 18, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (
www.apricusbio.com) announced today that Edward Cox, Vice President Corporate Development & Investor Relations, will present at the 2013 BIO International Convention on Wednesday, April 24, 2013 at 4:15 p.m. local time at McCormick Place, Chicago Bears Room, in Chicago, Illinois. Mr. Cox will present a company overview.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros
®, for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories, and Femprox
®, a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one approximately 400-patient Phase III study in China.
For further information on Apricus Bio, visit
http://www.apricusbio.com. You can also receive information at
CONTACT: Apricus Bio Investor Relations:
David Pitts or Lourdes Catala